• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Perion Network Cuts Revenue Outlook, Joins Skye Bioscience And Other Big Stocks Moving Lower In Monday's Pre-Market Session

    6/10/24 8:10:17 AM ET
    $ALEC
    $BWLP
    $CINT
    $ECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Transportation Services
    Consumer Discretionary
    Get the next $ALEC alert in real time by email

    U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Monday.

    Shares of Perion Network Ltd. (NASDAQ:PERI) fell sharply in today's pre-market trading after the company lowered its revenue forecast.

    Perion Network slashed its second-quarter revenue forecast from $118 million – $122 million to $106 million – $108 million. The company lowered its FY24 revenue forecast from $590 million – $610 million to $490 million – $510 million.

    Perion Network shares dipped 21% to $9.74 in pre-market trading.

    Here are some big stocks recording losses in today's pre-market trading session.

    • Skye Bioscience, Inc. (NASDAQ:SKYE) shares tumbled 45.2% to $6.00 in pre-market trading as the company said its Phase 2a clinical trial of SBI-100 Ophthalmic Emulsion in patients with primary open-angle glaucoma or ocular hypertension did not meet its primary endpoint for lowering intraocular pressure.
    • CI&T Inc. (NYSE:CINT) shares declined 17.7% to $4.00 in pre-market trading.
    • Sify Technologies Limited (NASDAQ:SIFY) shares dipped 10.7% to $0.7413 in pre-market trading after the company announced intent to delist ADS Rights from the Nasdaq Capital Market.
    • Ecarx Holdings Inc. (NASDAQ:ECX) shares fell 9.2% to $0.98 in pre-market trading.
    • Alector Inc (NASDAQ:ALEC) shares declined 8.3% to $4.00 in pre-market trading.
    • TeraWulf Inc. (NASDAQ:WULF) shares fell 5.8% to $2.91 in pre-market trading after declining around 4% on Friday.
    • BW LPG Limited (NYSE:BWLP) shares fell 4.2% to $18.86 in pre-market trading.
    • Palantir Technologies Inc. (NYSE:PLTR) shares fell 3.6% to $22.48 in pre-market trading.
    • Rush Street Interactive, Inc. (NYSE:RSI) shares fell 3.4% to $8.60 in  pre-market trading.

    Now Read This: Calavo Growers, Yext And 3 Stocks To Watch Heading Into Monday

    Don't forget to check out our premarket coverage here

    Get the next $ALEC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALEC
    $BWLP
    $CINT
    $ECX

    CompanyDatePrice TargetRatingAnalyst
    Palantir Technologies Inc.
    $PLTR
    2/18/2026$195.00Neutral → Outperform
    Mizuho
    Rush Street Interactive Inc.
    $RSI
    2/18/2026$24.00Mkt Perform → Mkt Outperform
    Citizens
    Palantir Technologies Inc.
    $PLTR
    2/10/2026$180.00Neutral → Buy
    Daiwa Securities
    TeraWulf Inc.
    $WULF
    2/9/2026$37.00Overweight
    Morgan Stanley
    Palantir Technologies Inc.
    $PLTR
    2/3/2026$205.00Hold → Buy
    HSBC Securities
    Palantir Technologies Inc.
    $PLTR
    2/3/2026$190.00Market Perform → Outperform
    Northland Capital
    Palantir Technologies Inc.
    $PLTR
    2/3/2026$200.00Neutral → Outperform
    Robert W. Baird
    Palantir Technologies Inc.
    $PLTR
    2/2/2026Mkt Perform → Outperform
    William Blair
    More analyst ratings

    $ALEC
    $BWLP
    $CINT
    $ECX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rush Street Interactive upgraded by Citizens with a new price target

    Citizens upgraded Rush Street Interactive from Mkt Perform to Mkt Outperform and set a new price target of $24.00

    2/18/26 7:51:45 AM ET
    $RSI
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Palantir Technologies upgraded by Mizuho with a new price target

    Mizuho upgraded Palantir Technologies from Neutral to Outperform and set a new price target of $195.00

    2/18/26 7:51:45 AM ET
    $PLTR
    Computer Software: Prepackaged Software
    Technology

    Palantir Technologies upgraded by Daiwa Securities with a new price target

    Daiwa Securities upgraded Palantir Technologies from Neutral to Buy and set a new price target of $180.00

    2/10/26 7:57:53 AM ET
    $PLTR
    Computer Software: Prepackaged Software
    Technology

    $ALEC
    $BWLP
    $CINT
    $ECX
    SEC Filings

    View All

    SEC Form 144 filed by Palantir Technologies Inc.

    144 - Palantir Technologies Inc. (0001321655) (Subject)

    2/20/26 4:47:15 PM ET
    $PLTR
    Computer Software: Prepackaged Software
    Technology

    SEC Form 144 filed by Palantir Technologies Inc.

    144 - Palantir Technologies Inc. (0001321655) (Subject)

    2/20/26 4:27:24 PM ET
    $PLTR
    Computer Software: Prepackaged Software
    Technology

    SEC Form 8-K filed by Skye Bioscience Inc.

    8-K - Skye Bioscience, Inc. (0001516551) (Filer)

    2/20/26 4:05:12 PM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALEC
    $BWLP
    $CINT
    $ECX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CI&T To Announce Fourth Quarter 2025 Results on March 11, 2026

    CI&T (NYSE:CINT, "Company")), a global partner in tech-integrated business solutions, announces that it will report its fourth quarter and full-year 2025 financial results after the market closes on March 11, 2026. Following the earnings release, CI&T's senior management team will host a video conference call to discuss the financial and operating results on the same day, March 11, at 4:30 PM Eastern Time / 5:30 PM BRT. The video conference call can be accessed at the Company's Investor Relations website at investors.ciandt.com or through the following link: youtube.com/live/2tEAFb3a0WA?feature=share. About CI&T CI&T (NYSE:CINT) is a global technology transformation specialist for 1

    2/23/26 8:17:00 AM ET
    $CINT
    EDP Services
    Technology

    AI-Controlled Intelligent Radar Market Accelerates Toward $50+ Billion Opportunity

    Next-Generation Defense Systems Drive High-Growth, AI-Powered Upgrade Cycle Across Global MilitariesMarket News Updates News Commentary NEW YORK, Feb. 19, 2026 /CNW/ -- The AI-Controlled Intelligent Radar Systems industry is quickly becoming one of the most important areas in modern defense technology. In simple terms, these systems combine traditional radar hardware with artificial intelligence software that can 'think' and adapt in real time. Instead of relying only on human operators to interpret signals, AI helps radar systems automatically identify drones, missiles, aircraft, and other threats faster and more accurately. That means fewer false alarms, better tracking, and stronger overa

    2/19/26 9:00:00 AM ET
    $LHX
    $PLTR
    $RTX
    Industrial Machinery/Components
    Industrials
    Computer Software: Prepackaged Software
    Technology

    Rackspace and Palantir Partner to Run Foundry and AIP in Production with Governed Managed Operations

    SAN ANTONIO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Rackspace Technology® (NASDAQ:RXT), a hybrid multicloud and AI solutions company, and Palantir Technologies Inc. (NASDAQ:PLTR), a global leader in operational artificial intelligence platforms, today announced a strategic partnership to help enterprises rapidly deploy and operate Palantir's Foundry and Artificial Intelligence Platform (AIP) in production to achieve measurable business outcomes. Through this partnership, Rackspace's governed operating model will provide consistent security, operating controls and compliance from edge to core to cloud enabling customers to deploy AI use cases with Palantir in production in weeks or months versu

    2/18/26 8:15:00 AM ET
    $PLTR
    $RXT
    Computer Software: Prepackaged Software
    Technology
    Computer Software: Programming Data Processing

    $ALEC
    $BWLP
    $CINT
    $ECX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Schwartz Richard Todd sold $4,155,247 worth of shares (247,114 units at $16.82), decreasing direct ownership by 26% to 701,934 units (SEC Form 4)

    4 - Rush Street Interactive, Inc. (0001793659) (Issuer)

    2/19/26 6:13:32 PM ET
    $RSI
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form 4 filed by Director Schwab Andrew J.

    4 - Skye Bioscience, Inc. (0001516551) (Issuer)

    2/9/26 9:06:29 PM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Grayson Paul A.

    4 - Skye Bioscience, Inc. (0001516551) (Issuer)

    2/9/26 8:54:56 PM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALEC
    $BWLP
    $CINT
    $ECX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bucella Michael C. converted options into 35,487 shares and bought $50,178 worth of shares (4,178 units at $12.01), increasing direct ownership by 17% to 266,958 units (SEC Form 4)

    4 - TERAWULF INC. (0001083301) (Issuer)

    12/11/25 6:38:34 PM ET
    $WULF
    EDP Services
    Technology

    Planishek Heather A. bought $1,161,400 worth of shares (10,000 units at $116.14), increasing direct ownership by 21% to 58,006 units (SEC Form 4)

    4 - Palantir Technologies Inc. (0001321655) (Issuer)

    5/12/25 7:57:39 PM ET
    $PLTR
    Computer Software: Prepackaged Software
    Technology

    Director Bucella Michael C. bought $19,999 worth of shares (4,796 units at $4.17), increasing direct ownership by 2% to 205,632 units (SEC Form 4)

    4 - TERAWULF INC. (0001083301) (Issuer)

    1/31/25 6:12:38 PM ET
    $WULF
    EDP Services
    Technology

    $ALEC
    $BWLP
    $CINT
    $ECX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Alector Inc.

    SC 13G - Alector, Inc. (0001653087) (Subject)

    12/6/24 5:30:28 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Rush Street Interactive Inc.

    SC 13D/A - Rush Street Interactive, Inc. (0001793659) (Subject)

    12/4/24 6:04:56 PM ET
    $RSI
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Rush Street Interactive Inc.

    SC 13D/A - Rush Street Interactive, Inc. (0001793659) (Subject)

    11/27/24 4:47:40 PM ET
    $RSI
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $ALEC
    $BWLP
    $CINT
    $ECX
    Leadership Updates

    Live Leadership Updates

    View All

    Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide

    22.3% total weight loss at 52 weeks with nimacimab (200 mg dose) + semaglutide (2.4 mg) combination — no plateau observed, suggesting potential for further efficacy beyond one year and at higher nimacimab dosesWeight regain during treatment interruption reduced by over 50% — nimacimab + semaglutide cohort regained only 17.8% of lost weight vs. 37.3% for semaglutide alone during 13-week off-therapy follow-up, demonstrating durability advantageStrong safety and tolerability profile maintained — no serious adverse events or adverse events of special interest reported during the 52-week extension period SAN DIEGO, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye")

    2/2/26 7:00:00 AM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sify reports Consolidated Financial Results for Q3 FY 2025-26

    Revenues of INR 11596 Million. EBITDA of INR 2470 Million. Loss for the period INR 329 Million. CHENNAI, India, Jan. 12, 2026 (GLOBE NEWSWIRE) -- DETAILS OF EARNING CALL         January 13, 2026 | 8:30 AM ET | 07:00 PM IST Participant Dial in: To join: +1-888-506-0062 (Toll Free in the U.S. or Canada) or +1-973-528-0011 (International) | Access Code: 910873 On the call: Mr. Raju Vegesna, Chairman of the Board and Mr. M P Vijay Kumar, Executive Director & Group CFO Live webcast: https://www.webcaster4.com/Webcast/Page/2184/53449. Archives: +1-877-481-4010 (Toll Free in the U.S. or Canada) or +1-919-882-2331 (International). Passcode 53449 Replay is available unti

    1/12/26 8:45:23 AM ET
    $SIFY
    Computer Software: Programming Data Processing
    Technology

    Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer

    SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that Neil Berkley, who has served as Alector's Chief Business Officer (CBO) since March 2024, and CBO and Interim Chief Financial Officer (CFO) since June 2025, has been appointed CFO, effective December 10, 2025. Mr. Berkley will continue to serve as CBO. "Neil has demonstrated exceptional leadership, judgment, strategic insight, and an unwavering commitment to Alector's mission," said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. "His

    12/12/25 4:05:00 PM ET
    $ALEC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALEC
    $BWLP
    $CINT
    $ECX
    Financials

    Live finance-specific insights

    View All

    CI&T To Announce Fourth Quarter 2025 Results on March 11, 2026

    CI&T (NYSE:CINT, "Company")), a global partner in tech-integrated business solutions, announces that it will report its fourth quarter and full-year 2025 financial results after the market closes on March 11, 2026. Following the earnings release, CI&T's senior management team will host a video conference call to discuss the financial and operating results on the same day, March 11, at 4:30 PM Eastern Time / 5:30 PM BRT. The video conference call can be accessed at the Company's Investor Relations website at investors.ciandt.com or through the following link: youtube.com/live/2tEAFb3a0WA?feature=share. About CI&T CI&T (NYSE:CINT) is a global technology transformation specialist for 1

    2/23/26 8:17:00 AM ET
    $CINT
    EDP Services
    Technology

    Perion Reports Fourth Quarter Results

    Contribution ex-TAC Grew by 19%, Adjusted EBITDA up 53% YoY Provides 2026 Guidance and Unveils 2028 Targets: Perion One Platform 20% Organic Contribution ex-TAC 3-Year CAGR and Consolidated Adjusted EBITDA margin of 28% Perion Network Ltd. (NASDAQ and TASE: PERI), an advanced technology leader solving for the complexities of digital advertising through AI-native execution infrastructure, today reported its financial results for the fourth quarter and full year ended December 31, 2025. "Our fourth-quarter performance, highlighted by a 19% year-over-year increase in Contribution ex-TAC and a 53% surge in Adjusted EBITDA, demonstrates that Perion One is winning," said Tal Jacobson, CEO

    2/18/26 7:00:00 AM ET
    $PERI
    EDP Services
    Technology

    ECARX Announces Fourth Quarter 2025 Unaudited Financial Results

    LONDON, Feb. 12, 2026 /PRNewswire/ -- ECARX Holdings Inc. (NASDAQ:ECX) ("ECARX" or the "Company"), a global mobility tech provider, today announced unaudited financial results for the quarter ended December 31, 2025. Ziyu Shen, ECARX Chairman and CEO, commented, "The fourth quarter was a critical inflection point for us, marking the start of our next phase of sustainable, profitable growth as we realize our vision of becoming a leading AI technology provider for the global automotive industry. We delivered our second consecutive quarter of positive net income and positive adjusted EBITDA, as revenue hit a historic high of US$304.7 million, up 13% year-over-year. For the full year, we delive

    2/12/26 7:29:00 AM ET
    $ECX
    EDP Services
    Technology